Serveur d'exploration sur l'Indium

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Simultaneous administration of111In-human immunoglobulin and99mTc-HMPAO labelled leucocytes in inflammatory bowel disease

Identifieur interne : 000091 ( Main/Exploration ); précédent : 000090; suivant : 000092

Simultaneous administration of111In-human immunoglobulin and99mTc-HMPAO labelled leucocytes in inflammatory bowel disease

Auteurs : RBID : ISTEX:259_1995_Article_BF01254568.pdf

English descriptors

Abstract

Technetium-99m hexamethylpropylene amine oxime (HMPAO) labelled leucocytes and indium-111 polyclonal immunoglobulin (IgG) were simultaneously injected into a group of 27 patients routinely referred for the investigation of inflammatory bowel disease (IBD). Ten-minute anterior abdomen and tail on detector views were obtained at 30 min, 4 h and 24 h p.i. of both tracers. The diagnosis of IBD was obtained in all cases by endoscopy with biopsy and/or surgery. Images were blindly evaluated by two experienced observers who only knew of the clinical suspicion of IBD. IBD was confirmed in 20 patients (12 with Crohn's disease and eight with ulcerative colitis). Sensitivity, specificity and accuracy were 100%, 85% and 96% respectively for labelled leucocytes and 70%, 85% and 74% for IgG. Both IgG and leucocyte scans were normal in six out of seven patients in whom a diagnosis of IBD was excluded; the remaining patient, with ischaemic colitis, was falsely positive with both agents. As far as disease extension is concerned, the IgG study localized 27 diseased segments, whereas 49 were seen with the leucocyte study. Eighty-four segments were normal and 25 showed tracer uptake with both agents. Twenty-four were positive only with the leucocyte study and two were positive only with the IgG study. Agreement between the agents was 80.7%. These results confirm that111In-human polyclonal scintigraphy is less sensitive than99mTc-HMPAO scintigraphy both for the diagnosis of IBD and in the evaluation of disease extension. Nevertheless, if leucocyte labelling is not available, labelled IgG can be used only for diagnostic purposes.

DOI: 10.1007/BF01254568

Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title>Simultaneous administration of111In-human immunoglobulin and99mTc-HMPAO labelled leucocytes in inflammatory bowel disease</title>
<author>
<name>L. Mairal</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Nuclear Medicine, CSUB, Hospital Princeps d'Espanya, Barcelona, Spain</mods:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Nuclear Medicine, CSUB, Hospital Princeps d'Espanya, Barcelona</wicri:regionArea>
<wicri:noRegion>Barcelona</wicri:noRegion>
</affiliation>
</author>
<author>
<name>P. A. de Lima</name>
<affiliation wicri:level="1">
<mods:affiliation>Bolsista do Conselho Nacional de Desenvolvimento Científico e Tecnologico, Brazil</mods:affiliation>
<country xml:lang="fr">Brésil</country>
<wicri:regionArea>Bolsista do Conselho Nacional de Desenvolvimento Científico e Tecnologico</wicri:regionArea>
</affiliation>
</author>
<author>
<name>J. Martin-Comin</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Nuclear Medicine, CSUB, Hospital Princeps d'Espanya, Barcelona, Spain</mods:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Nuclear Medicine, CSUB, Hospital Princeps d'Espanya, Barcelona</wicri:regionArea>
<wicri:noRegion>Barcelona</wicri:noRegion>
</affiliation>
</author>
<author>
<name>C. Baliellas</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Gastroenterology, CSUB, Hospital Princeps d'Espanya, Barcelona, Spain</mods:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Gastroenterology, CSUB, Hospital Princeps d'Espanya, Barcelona</wicri:regionArea>
<wicri:noRegion>Barcelona</wicri:noRegion>
</affiliation>
</author>
<author>
<name>X. Xiol</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Gastroenterology, CSUB, Hospital Princeps d'Espanya, Barcelona, Spain</mods:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Gastroenterology, CSUB, Hospital Princeps d'Espanya, Barcelona</wicri:regionArea>
<wicri:noRegion>Barcelona</wicri:noRegion>
</affiliation>
</author>
<author>
<name>M. Roca</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Nuclear Medicine, CSUB, Hospital Princeps d'Espanya, Barcelona, Spain</mods:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Nuclear Medicine, CSUB, Hospital Princeps d'Espanya, Barcelona</wicri:regionArea>
<wicri:noRegion>Barcelona</wicri:noRegion>
</affiliation>
</author>
<author>
<name>Y. Ricart</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Nuclear Medicine, CSUB, Hospital Princeps d'Espanya, Barcelona, Spain</mods:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Nuclear Medicine, CSUB, Hospital Princeps d'Espanya, Barcelona</wicri:regionArea>
<wicri:noRegion>Barcelona</wicri:noRegion>
</affiliation>
</author>
<author>
<name>M. Ramos</name>
<affiliation wicri:level="1">
<mods:affiliation>Department of Nuclear Medicine, CSUB, Hospital Princeps d'Espanya, Barcelona, Spain</mods:affiliation>
<country xml:lang="fr">Espagne</country>
<wicri:regionArea>Department of Nuclear Medicine, CSUB, Hospital Princeps d'Espanya, Barcelona</wicri:regionArea>
<wicri:noRegion>Barcelona</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="RBID">ISTEX:259_1995_Article_BF01254568.pdf</idno>
<date when="1995">1995</date>
<idno type="doi">10.1007/BF01254568</idno>
<idno type="wicri:Area/Main/Corpus">000465</idno>
<idno type="wicri:Area/Main/Curation">000465</idno>
<idno type="wicri:Area/Main/Exploration">000091</idno>
</publicationStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Dual tracer studies</term>
<term>Indium-111 immunoglobulin</term>
<term>Inflammatory bowel disease</term>
<term>Labelled leucocytes</term>
<term>Technetium-99m hexamethylpropylene amine oxime</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="eng">Technetium-99m hexamethylpropylene amine oxime (HMPAO) labelled leucocytes and indium-111 polyclonal immunoglobulin (IgG) were simultaneously injected into a group of 27 patients routinely referred for the investigation of inflammatory bowel disease (IBD). Ten-minute anterior abdomen and tail on detector views were obtained at 30 min, 4 h and 24 h p.i. of both tracers. The diagnosis of IBD was obtained in all cases by endoscopy with biopsy and/or surgery. Images were blindly evaluated by two experienced observers who only knew of the clinical suspicion of IBD. IBD was confirmed in 20 patients (12 with Crohn's disease and eight with ulcerative colitis). Sensitivity, specificity and accuracy were 100%, 85% and 96% respectively for labelled leucocytes and 70%, 85% and 74% for IgG. Both IgG and leucocyte scans were normal in six out of seven patients in whom a diagnosis of IBD was excluded; the remaining patient, with ischaemic colitis, was falsely positive with both agents. As far as disease extension is concerned, the IgG study localized 27 diseased segments, whereas 49 were seen with the leucocyte study. Eighty-four segments were normal and 25 showed tracer uptake with both agents. Twenty-four were positive only with the leucocyte study and two were positive only with the IgG study. Agreement between the agents was 80.7%. These results confirm that111In-human polyclonal scintigraphy is less sensitive than99mTc-HMPAO scintigraphy both for the diagnosis of IBD and in the evaluation of disease extension. Nevertheless, if leucocyte labelling is not available, labelled IgG can be used only for diagnostic purposes.</div>
</front>
</TEI>
<mods xsi:schemaLocation="http://www.loc.gov/mods/v3 file:///applis/istex/home/loadistex/home/etc/xsd/mods.xsd" version="3.4" istexId="514aca33a4ac3d1559a79414f6c9ecfc83433e0b">
<titleInfo lang="eng">
<title>Simultaneous administration of111In-human immunoglobulin and99mTc-HMPAO labelled leucocytes in inflammatory bowel disease</title>
</titleInfo>
<name type="personal">
<namePart type="given">L.</namePart>
<namePart type="family">Mairal</namePart>
<role>
<roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, CSUB, Hospital Princeps d'Espanya, Barcelona, Spain</affiliation>
</name>
<name type="personal">
<namePart type="given">P. A.</namePart>
<namePart type="family">de Lima</namePart>
<role>
<roleTerm type="text">author</roleTerm>
</role>
<affiliation>Bolsista do Conselho Nacional de Desenvolvimento Científico e Tecnologico, Brazil</affiliation>
</name>
<name type="personal">
<namePart type="given">J.</namePart>
<namePart type="family">Martin-Comin</namePart>
<role>
<roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, CSUB, Hospital Princeps d'Espanya, Barcelona, Spain</affiliation>
</name>
<name type="personal">
<namePart type="given">C.</namePart>
<namePart type="family">Baliellas</namePart>
<role>
<roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Gastroenterology, CSUB, Hospital Princeps d'Espanya, Barcelona, Spain</affiliation>
</name>
<name type="personal">
<namePart type="given">X.</namePart>
<namePart type="family">Xiol</namePart>
<role>
<roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Gastroenterology, CSUB, Hospital Princeps d'Espanya, Barcelona, Spain</affiliation>
</name>
<name type="personal">
<namePart type="given">M.</namePart>
<namePart type="family">Roca</namePart>
<role>
<roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, CSUB, Hospital Princeps d'Espanya, Barcelona, Spain</affiliation>
</name>
<name type="personal">
<namePart type="given">Y.</namePart>
<namePart type="family">Ricart</namePart>
<role>
<roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, CSUB, Hospital Princeps d'Espanya, Barcelona, Spain</affiliation>
</name>
<name type="personal">
<namePart type="given">M.</namePart>
<namePart type="family">Ramos</namePart>
<role>
<roleTerm type="text">author</roleTerm>
</role>
<affiliation>Department of Nuclear Medicine, CSUB, Hospital Princeps d'Espanya, Barcelona, Spain</affiliation>
</name>
<typeOfResource>text</typeOfResource>
<genre>Original Article</genre>
<genre>Original Paper</genre>
<originInfo>
<publisher>Springer-Verlag, Berlin/Heidelberg</publisher>
<dateCreated encoding="w3cdtf">1994-10-08</dateCreated>
<dateValid encoding="w3cdtf">2005-02-18</dateValid>
<copyrightDate encoding="w3cdtf">1995</copyrightDate>
</originInfo>
<language>
<languageTerm type="code" authority="iso639-2b">eng</languageTerm>
</language>
<physicalDescription>
<internetMediaType>text/html</internetMediaType>
</physicalDescription>
<abstract lang="eng">Technetium-99m hexamethylpropylene amine oxime (HMPAO) labelled leucocytes and indium-111 polyclonal immunoglobulin (IgG) were simultaneously injected into a group of 27 patients routinely referred for the investigation of inflammatory bowel disease (IBD). Ten-minute anterior abdomen and tail on detector views were obtained at 30 min, 4 h and 24 h p.i. of both tracers. The diagnosis of IBD was obtained in all cases by endoscopy with biopsy and/or surgery. Images were blindly evaluated by two experienced observers who only knew of the clinical suspicion of IBD. IBD was confirmed in 20 patients (12 with Crohn's disease and eight with ulcerative colitis). Sensitivity, specificity and accuracy were 100%, 85% and 96% respectively for labelled leucocytes and 70%, 85% and 74% for IgG. Both IgG and leucocyte scans were normal in six out of seven patients in whom a diagnosis of IBD was excluded; the remaining patient, with ischaemic colitis, was falsely positive with both agents. As far as disease extension is concerned, the IgG study localized 27 diseased segments, whereas 49 were seen with the leucocyte study. Eighty-four segments were normal and 25 showed tracer uptake with both agents. Twenty-four were positive only with the leucocyte study and two were positive only with the IgG study. Agreement between the agents was 80.7%. These results confirm that111In-human polyclonal scintigraphy is less sensitive than99mTc-HMPAO scintigraphy both for the diagnosis of IBD and in the evaluation of disease extension. Nevertheless, if leucocyte labelling is not available, labelled IgG can be used only for diagnostic purposes.</abstract>
<subject lang="eng">
<genre>Key words</genre>
<topic>Technetium-99m hexamethylpropylene amine oxime</topic>
<topic>Labelled leucocytes</topic>
<topic>Indium-111 immunoglobulin</topic>
<topic>Inflammatory bowel disease</topic>
<topic>Dual tracer studies</topic>
</subject>
<relatedItem type="series">
<titleInfo type="abbreviated">
<title>Eur J Nucl Med</title>
</titleInfo>
<titleInfo>
<title>European Journal of Nuclear Medicine</title>
<partNumber>Year: 1995</partNumber>
<partNumber>Volume: 22</partNumber>
<partNumber>Number: 7</partNumber>
</titleInfo>
<genre>Archive Journal</genre>
<originInfo>
<dateIssued encoding="w3cdtf">1995-07-01</dateIssued>
<copyrightDate encoding="w3cdtf">1995</copyrightDate>
</originInfo>
<subject usage="primary">
<topic>Medicine & Public Health</topic>
<topic>Imaging / Radiology</topic>
<topic>Nuclear Medicine</topic>
</subject>
<identifier type="issn">0340-6997</identifier>
<identifier type="issn">Electronic: 1619-7089</identifier>
<identifier type="matrixNumber">259</identifier>
<identifier type="local">IssueArticleCount: 19</identifier>
<recordInfo>
<recordOrigin>Springer-Verlag, 1995</recordOrigin>
</recordInfo>
</relatedItem>
<identifier type="doi">10.1007/BF01254568</identifier>
<identifier type="matrixNumber">Art10</identifier>
<identifier type="local">BF01254568</identifier>
<accessCondition type="use and reproduction">MetadataGrant: OpenAccess</accessCondition>
<accessCondition type="use and reproduction">AbstractGrant: OpenAccess</accessCondition>
<accessCondition type="restriction on access">BodyPDFGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">BodyHTMLGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">BibliographyGrant: Restricted</accessCondition>
<accessCondition type="restriction on access">ESMGrant: Restricted</accessCondition>
<part>
<extent unit="pages">
<start>664</start>
<end>670</end>
</extent>
</part>
<recordInfo>
<recordOrigin>Springer-Verlag, 1995</recordOrigin>
<recordIdentifier>259_1995_Article_BF01254568.pdf</recordIdentifier>
</recordInfo>
</mods>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=IndiumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000091 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000091 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=   *** parameter Area/wikiCode missing *** 
   |area=    IndiumV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:259_1995_Article_BF01254568.pdf
   |texte=   Simultaneous administration of111In-human immunoglobulin and99mTc-HMPAO labelled leucocytes in inflammatory bowel disease
}}

Wicri

This area was generated with Dilib version V0.5.81.
Data generation: Mon Aug 25 10:35:12 2014. Site generation: Thu Mar 7 10:08:40 2024